Striated Muscle Antibodies, IgG
Striated muscle antibodies are autoantibodies directed against intracellular muscle proteins such as titin, ryanodine receptor, and voltage-gated potassium channel Kv1.4. They are most often detected in patients with myasthenia gravis (MG), an autoimmune neuromuscular disorder characterized by impaired transmission at the neuromuscular junction due to antibody-mediated blockade of acetylcholine receptors. Although not all MG patients produce striated muscle antibodies, they are particularly common in late-onset MG and in cases associated with thymoma.
The prevalence of specific subtypes varies: anti-titin antibodies occur in ~20–40% of MG cases, anti-ryanodine receptor in 13–38%, and anti-Kv1.4 in 12–15%. These antibodies may be present alone, but more commonly they coexist with anti-acetylcholine receptor antibodies, amplifying disease severity. Their presence indicates an underlying autoimmune mechanism that compromises neuromuscular function.
Clinically, striated muscle antibodies are associated with more severe forms of MG, especially when anti-ryanodine receptor antibodies are present, which correlate with significant muscle weakness and increased risk of myositis and myocarditis. Patients with anti-Kv1.4 antibodies are at risk for life-threatening arrhythmias including ventricular tachycardia, sick sinus syndrome, and complete atrioventricular block. Rarely, autoantibodies to myosin, actin, desmin, or α-actinin have been reported.
Outside MG, striated muscle antibodies may appear in Lambert-Eaton myasthenic syndrome, small-cell lung carcinoma, breast carcinoma, autoimmune liver disorders, bone marrow transplant with GVHD, and in patients treated with D-penicillamine. Their detection, particularly in MG patients with thymoma, is strongly linked with poor prognosis and severe disease phenotype.
- As an aid in the diagnostic of myasthenia gravis
- Prognostic indicator for disease severity and systemic involvement
Positive: Indicates presence of striated muscle antibodies; suggests myasthenia gravis with increased risk of thymoma, myocarditis, or more severe disease course. Subtyping (anti-titin, anti-RyR, anti-Kv1.4) provides prognostic value.
Negative: No significant autoantibody detected. Does not exclude MG, as some patients only express AChR or MuSK antibodies.
Negative (<1:100)
Serum, SST.
Stability
- Ambient: 1-3 days
- Refrigerated: 7 days
- Frozen: 1 month
- Arch Neurol. 2005 Mar;62(3):442-6. [PMID: 15767509]
- Autoimmune Dis. 2011;2011:740583. [PMID: 21785709]
- Sci Rep. 2019 Mar 27;9(1):5284. [PMID: 30918333]
- Expert Rev Clin Immunol. 2012 Jul;8(5):427-38. [PMID: 22882218]
- Arch Neurol. 2007 Aug;64(8):1121-4. [PMID: 17698702]